| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 60 | 2024 | 1851 | 11.990 |
Why?
|
| Soft Tissue Neoplasms | 37 | 2024 | 930 | 8.610 |
Why?
|
| Retroperitoneal Neoplasms | 21 | 2024 | 296 | 6.690 |
Why?
|
| Liposarcoma | 16 | 2024 | 248 | 4.170 |
Why?
|
| Extremities | 13 | 2024 | 311 | 4.020 |
Why?
|
| Gastrointestinal Stromal Tumors | 9 | 2024 | 318 | 2.510 |
Why?
|
| Fibromatosis, Aggressive | 7 | 2024 | 110 | 2.360 |
Why?
|
| Neoplasm Recurrence, Local | 28 | 2024 | 10409 | 2.030 |
Why?
|
| Sentinel Lymph Node | 5 | 2023 | 241 | 1.850 |
Why?
|
| Torso | 7 | 2024 | 75 | 1.650 |
Why?
|
| Leiomyosarcoma | 7 | 2024 | 253 | 1.270 |
Why?
|
| Gastrointestinal Neoplasms | 5 | 2024 | 629 | 1.140 |
Why?
|
| Lymph Nodes | 10 | 2023 | 3081 | 1.090 |
Why?
|
| Neoplasm Staging | 13 | 2022 | 14037 | 1.080 |
Why?
|
| Humans | 130 | 2024 | 270804 | 0.960 |
Why?
|
| Surgical Oncology | 4 | 2023 | 212 | 0.940 |
Why?
|
| Survival Rate | 25 | 2024 | 12535 | 0.920 |
Why?
|
| Pancreatectomy | 5 | 2019 | 696 | 0.920 |
Why?
|
| Neoadjuvant Therapy | 7 | 2024 | 5247 | 0.870 |
Why?
|
| Prognosis | 26 | 2024 | 22533 | 0.790 |
Why?
|
| Postoperative Complications | 9 | 2024 | 5681 | 0.790 |
Why?
|
| Follow-Up Studies | 22 | 2024 | 15280 | 0.750 |
Why?
|
| Pancreatic Neoplasms | 10 | 2015 | 5264 | 0.740 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 3841 | 0.730 |
Why?
|
| Wounds and Injuries | 2 | 2023 | 424 | 0.730 |
Why?
|
| Retrospective Studies | 48 | 2024 | 39982 | 0.720 |
Why?
|
| Sentinel Lymph Node Biopsy | 7 | 2023 | 1464 | 0.720 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2022 | 214 | 0.700 |
Why?
|
| Combined Modality Therapy | 14 | 2024 | 9054 | 0.700 |
Why?
|
| Middle Aged | 56 | 2024 | 90569 | 0.690 |
Why?
|
| Lymphatic Metastasis | 9 | 2023 | 4969 | 0.680 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2021 | 162 | 0.680 |
Why?
|
| Aged | 49 | 2024 | 73640 | 0.660 |
Why?
|
| Hospitals, High-Volume | 2 | 2024 | 76 | 0.660 |
Why?
|
| Tumor Burden | 4 | 2019 | 2033 | 0.650 |
Why?
|
| Histiocytoma, Malignant Fibrous | 2 | 2016 | 49 | 0.640 |
Why?
|
| Carcinoma, Pancreatic Ductal | 6 | 2015 | 1833 | 0.640 |
Why?
|
| Adult | 49 | 2024 | 82073 | 0.620 |
Why?
|
| Neuroendocrine Tumors | 3 | 2020 | 656 | 0.620 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 51 | 0.620 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2010 | 215 | 0.600 |
Why?
|
| Radiosurgery | 2 | 2024 | 1389 | 0.600 |
Why?
|
| Aged, 80 and over | 30 | 2024 | 31117 | 0.590 |
Why?
|
| Neoplasms | 11 | 2024 | 15951 | 0.570 |
Why?
|
| Databases, Factual | 6 | 2019 | 2261 | 0.560 |
Why?
|
| Skin Neoplasms | 4 | 2024 | 4900 | 0.550 |
Why?
|
| Water | 1 | 2018 | 386 | 0.540 |
Why?
|
| Male | 54 | 2024 | 128520 | 0.530 |
Why?
|
| Female | 63 | 2024 | 148936 | 0.530 |
Why?
|
| Clinical Protocols | 1 | 2018 | 476 | 0.530 |
Why?
|
| Adenocarcinoma | 7 | 2018 | 7920 | 0.530 |
Why?
|
| Fibrosarcoma | 1 | 2016 | 143 | 0.520 |
Why?
|
| Smad4 Protein | 1 | 2016 | 201 | 0.500 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2017 | 232 | 0.500 |
Why?
|
| Paraganglioma | 1 | 2017 | 200 | 0.500 |
Why?
|
| Neurofibromatosis 1 | 3 | 2024 | 159 | 0.500 |
Why?
|
| Vascular Neoplasms | 1 | 2016 | 112 | 0.490 |
Why?
|
| Education, Medical, Graduate | 2 | 2023 | 705 | 0.480 |
Why?
|
| Biomarkers, Tumor | 9 | 2024 | 10731 | 0.480 |
Why?
|
| Pheochromocytoma | 1 | 2017 | 310 | 0.470 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2015 | 706 | 0.470 |
Why?
|
| Curriculum | 1 | 2020 | 914 | 0.450 |
Why?
|
| Young Adult | 23 | 2024 | 22255 | 0.450 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 1338 | 0.430 |
Why?
|
| Quality of Health Care | 2 | 2018 | 614 | 0.420 |
Why?
|
| Registries | 2 | 2018 | 2212 | 0.420 |
Why?
|
| Guideline Adherence | 1 | 2017 | 626 | 0.420 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2017 | 527 | 0.420 |
Why?
|
| Intubation, Gastrointestinal | 2 | 2015 | 90 | 0.420 |
Why?
|
| Anxiety | 1 | 2020 | 1244 | 0.420 |
Why?
|
| Lactic Acid | 1 | 2014 | 312 | 0.410 |
Why?
|
| Insulinoma | 2 | 2011 | 53 | 0.410 |
Why?
|
| Research Design | 1 | 2020 | 1562 | 0.410 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 2395 | 0.390 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2010 | 1580 | 0.390 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2012 | 152 | 0.380 |
Why?
|
| Ampulla of Vater | 1 | 2012 | 160 | 0.380 |
Why?
|
| Pancreatic Diseases | 1 | 2012 | 113 | 0.370 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2014 | 485 | 0.360 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 637 | 0.360 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 1033 | 0.350 |
Why?
|
| Margins of Excision | 3 | 2024 | 315 | 0.340 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2022 | 2272 | 0.320 |
Why?
|
| Clinical Decision-Making | 2 | 2024 | 536 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 16751 | 0.310 |
Why?
|
| Reoperation | 3 | 2024 | 1391 | 0.310 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2396 | 0.300 |
Why?
|
| Bone Neoplasms | 4 | 2022 | 2674 | 0.300 |
Why?
|
| Neovascularization, Pathologic | 3 | 2009 | 1587 | 0.300 |
Why?
|
| Immune System | 1 | 2009 | 275 | 0.300 |
Why?
|
| Imatinib Mesylate | 3 | 2021 | 1691 | 0.300 |
Why?
|
| Treatment Outcome | 20 | 2024 | 33859 | 0.280 |
Why?
|
| Surgical Procedures, Operative | 2 | 2021 | 359 | 0.270 |
Why?
|
| Neoplasm Metastasis | 3 | 2024 | 5332 | 0.270 |
Why?
|
| Neoplasm Grading | 5 | 2018 | 1828 | 0.270 |
Why?
|
| Preoperative Care | 5 | 2024 | 1582 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 4 | 2022 | 4470 | 0.260 |
Why?
|
| Disease-Free Survival | 11 | 2021 | 10268 | 0.260 |
Why?
|
| B-Lymphocytes | 2 | 2024 | 1420 | 0.260 |
Why?
|
| Medical Oncology | 3 | 2024 | 1464 | 0.250 |
Why?
|
| Surgeons | 2 | 2022 | 493 | 0.250 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 1175 | 0.250 |
Why?
|
| Length of Stay | 5 | 2018 | 1998 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 7923 | 0.240 |
Why?
|
| United States | 8 | 2019 | 15834 | 0.240 |
Why?
|
| Ribonuclease H | 1 | 2024 | 18 | 0.240 |
Why?
|
| Cohort Studies | 8 | 2024 | 9464 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 6 | 2019 | 4054 | 0.230 |
Why?
|
| Breast Neoplasms | 7 | 2021 | 16246 | 0.230 |
Why?
|
| Osteosarcoma | 2 | 2022 | 951 | 0.220 |
Why?
|
| Consensus | 3 | 2023 | 1113 | 0.220 |
Why?
|
| Antineoplastic Agents | 7 | 2021 | 14639 | 0.220 |
Why?
|
| Cytokines | 2 | 2009 | 2804 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 4966 | 0.220 |
Why?
|
| Adenoviridae Infections | 1 | 2023 | 114 | 0.210 |
Why?
|
| Melanoma | 3 | 2020 | 5601 | 0.210 |
Why?
|
| Adolescent | 13 | 2022 | 32698 | 0.210 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2016 | 402 | 0.210 |
Why?
|
| Thigh | 1 | 2024 | 165 | 0.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 623 | 0.210 |
Why?
|
| Ganglioneuroma | 1 | 2022 | 44 | 0.200 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 701 | 0.200 |
Why?
|
| Cryosurgery | 1 | 2024 | 197 | 0.200 |
Why?
|
| Immunoenzyme Techniques | 3 | 2016 | 1188 | 0.200 |
Why?
|
| CpG Islands | 1 | 2024 | 669 | 0.200 |
Why?
|
| Hemipelvectomy | 1 | 2022 | 38 | 0.200 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 186 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 1270 | 0.200 |
Why?
|
| Prospective Studies | 5 | 2024 | 13422 | 0.190 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2022 | 74 | 0.190 |
Why?
|
| Proportional Hazards Models | 5 | 2019 | 5099 | 0.190 |
Why?
|
| Orthopedics | 1 | 2022 | 77 | 0.190 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 3706 | 0.190 |
Why?
|
| Neurofibrosarcoma | 2 | 2024 | 42 | 0.190 |
Why?
|
| Lymphadenopathy | 1 | 2022 | 94 | 0.190 |
Why?
|
| Surgical Flaps | 2 | 2024 | 891 | 0.180 |
Why?
|
| Salvage Therapy | 3 | 2018 | 2124 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 566 | 0.180 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2021 | 82 | 0.180 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2021 | 72 | 0.180 |
Why?
|
| Patient Selection | 4 | 2023 | 2032 | 0.180 |
Why?
|
| Dogs | 2 | 2021 | 1082 | 0.180 |
Why?
|
| Oncologists | 1 | 2023 | 136 | 0.180 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2021 | 162 | 0.180 |
Why?
|
| Pelvic Neoplasms | 1 | 2022 | 200 | 0.180 |
Why?
|
| Peritoneal Neoplasms | 3 | 2020 | 866 | 0.170 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 14885 | 0.170 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 94 | 0.170 |
Why?
|
| Reference Standards | 1 | 2021 | 369 | 0.170 |
Why?
|
| Pandemics | 4 | 2022 | 1608 | 0.170 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2020 | 37 | 0.170 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2019 | 17 | 0.170 |
Why?
|
| Lipoma | 1 | 2020 | 93 | 0.170 |
Why?
|
| Europe | 1 | 2021 | 650 | 0.170 |
Why?
|
| Watchful Waiting | 2 | 2021 | 293 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 705 | 0.170 |
Why?
|
| Sclerosis | 1 | 2019 | 76 | 0.160 |
Why?
|
| Enteral Nutrition | 2 | 2015 | 341 | 0.160 |
Why?
|
| Colitis | 1 | 2022 | 340 | 0.160 |
Why?
|
| Limb Salvage | 1 | 2020 | 165 | 0.160 |
Why?
|
| Decision Making | 2 | 2024 | 1249 | 0.160 |
Why?
|
| Laparoscopy | 1 | 2008 | 1304 | 0.160 |
Why?
|
| Pancreatic Fistula | 1 | 2019 | 102 | 0.160 |
Why?
|
| Mice, Nude | 5 | 2014 | 4331 | 0.160 |
Why?
|
| Free Tissue Flaps | 1 | 2023 | 374 | 0.160 |
Why?
|
| Doxorubicin | 2 | 2020 | 3147 | 0.160 |
Why?
|
| Disease Management | 1 | 2024 | 1092 | 0.160 |
Why?
|
| Vaccines | 1 | 2024 | 373 | 0.160 |
Why?
|
| Incidence | 3 | 2019 | 5824 | 0.160 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 309 | 0.160 |
Why?
|
| Biological Products | 1 | 2022 | 318 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2022 | 3429 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 879 | 0.150 |
Why?
|
| Interprofessional Relations | 1 | 2020 | 207 | 0.150 |
Why?
|
| Cooperative Behavior | 1 | 2020 | 306 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2021 | 6259 | 0.150 |
Why?
|
| Surgical Wound Infection | 1 | 2022 | 495 | 0.150 |
Why?
|
| Health Expenditures | 1 | 2020 | 202 | 0.150 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 4843 | 0.150 |
Why?
|
| Intestine, Small | 1 | 2021 | 524 | 0.150 |
Why?
|
| Retroperitoneal Space | 1 | 2017 | 156 | 0.150 |
Why?
|
| Chondrosarcoma | 1 | 2019 | 213 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2021 | 557 | 0.140 |
Why?
|
| Lymph Node Excision | 5 | 2023 | 2068 | 0.140 |
Why?
|
| Mice, Inbred NOD | 2 | 2009 | 896 | 0.140 |
Why?
|
| Radiotherapy | 3 | 2019 | 1858 | 0.140 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 690 | 0.140 |
Why?
|
| Sarcoma, Ewing | 1 | 2020 | 428 | 0.140 |
Why?
|
| Patient Readmission | 2 | 2018 | 571 | 0.140 |
Why?
|
| Neuroblastoma | 1 | 2022 | 711 | 0.130 |
Why?
|
| Peptides | 2 | 2014 | 1502 | 0.130 |
Why?
|
| Animals | 14 | 2021 | 61362 | 0.130 |
Why?
|
| DNA Repair | 1 | 2024 | 1906 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 1096 | 0.130 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 586 | 0.130 |
Why?
|
| Tumor Microenvironment | 5 | 2023 | 3054 | 0.130 |
Why?
|
| HCT116 Cells | 2 | 2014 | 354 | 0.130 |
Why?
|
| Colectomy | 1 | 2018 | 292 | 0.130 |
Why?
|
| Pneumonia | 1 | 2022 | 792 | 0.130 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 721 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 417 | 0.130 |
Why?
|
| Disease Progression | 3 | 2022 | 6881 | 0.130 |
Why?
|
| Rectum | 1 | 2018 | 480 | 0.130 |
Why?
|
| Health Personnel | 1 | 2021 | 650 | 0.130 |
Why?
|
| Piperazines | 2 | 2022 | 2143 | 0.130 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 2339 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 2018 | 275 | 0.120 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2019 | 521 | 0.120 |
Why?
|
| Pain, Postoperative | 1 | 2021 | 663 | 0.120 |
Why?
|
| Telemedicine | 1 | 2022 | 557 | 0.120 |
Why?
|
| Neutrophils | 2 | 2010 | 855 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2022 | 1476 | 0.120 |
Why?
|
| Texas | 3 | 2020 | 6445 | 0.120 |
Why?
|
| Mice, Transgenic | 5 | 2021 | 4198 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2024 | 2769 | 0.120 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2016 | 277 | 0.120 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2015 | 182 | 0.120 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 146 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2024 | 6766 | 0.110 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 757 | 0.110 |
Why?
|
| Time Factors | 4 | 2021 | 12979 | 0.110 |
Why?
|
| Macrophages | 3 | 2010 | 1334 | 0.110 |
Why?
|
| Mice | 12 | 2021 | 35420 | 0.110 |
Why?
|
| Risk Factors | 4 | 2024 | 17867 | 0.110 |
Why?
|
| Immunotherapy | 3 | 2024 | 3561 | 0.110 |
Why?
|
| Abdominal Neoplasms | 1 | 2015 | 251 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1233 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 1098 | 0.100 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 547 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 1301 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2010 | 266 | 0.100 |
Why?
|
| Quality of Life | 2 | 2024 | 4810 | 0.100 |
Why?
|
| Carcinoma, Islet Cell | 1 | 2011 | 35 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 657 | 0.100 |
Why?
|
| Heterografts | 1 | 2014 | 739 | 0.100 |
Why?
|
| Cell Death | 1 | 2014 | 685 | 0.100 |
Why?
|
| Gastric Emptying | 1 | 2012 | 99 | 0.100 |
Why?
|
| Pyrimidines | 2 | 2021 | 3671 | 0.100 |
Why?
|
| Diet, High-Fat | 1 | 2013 | 244 | 0.100 |
Why?
|
| Postoperative Care | 1 | 2015 | 727 | 0.100 |
Why?
|
| Transfection | 2 | 2014 | 3109 | 0.100 |
Why?
|
| Unnecessary Procedures | 1 | 2012 | 101 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 3930 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 496 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 2038 | 0.090 |
Why?
|
| Peptoids | 1 | 2010 | 4 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 1467 | 0.090 |
Why?
|
| Hyperthermia, Induced | 1 | 2015 | 514 | 0.090 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2023 | 165 | 0.090 |
Why?
|
| Neoplasm Transplantation | 2 | 2014 | 1553 | 0.090 |
Why?
|
| Disease Models, Animal | 4 | 2014 | 7323 | 0.090 |
Why?
|
| Cell Survival | 2 | 2014 | 3058 | 0.090 |
Why?
|
| Biomimetic Materials | 1 | 2010 | 39 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 1437 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 984 | 0.080 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 1240 | 0.080 |
Why?
|
| Survival Analysis | 5 | 2019 | 9281 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 1503 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 2348 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 1308 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 3190 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 7647 | 0.080 |
Why?
|
| Palpation | 1 | 2008 | 51 | 0.080 |
Why?
|
| Mice, SCID | 2 | 2010 | 1825 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 1581 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2009 | 291 | 0.080 |
Why?
|
| Platelet Transfusion | 1 | 2008 | 166 | 0.070 |
Why?
|
| Mitochondrial Proteins | 1 | 2010 | 377 | 0.070 |
Why?
|
| DNA Primers | 1 | 2010 | 1489 | 0.070 |
Why?
|
| SEER Program | 1 | 2011 | 1052 | 0.070 |
Why?
|
| Genomics | 1 | 2018 | 2834 | 0.070 |
Why?
|
| Age Factors | 2 | 2018 | 5443 | 0.070 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2010 | 551 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1404 | 0.070 |
Why?
|
| Bevacizumab | 1 | 2009 | 967 | 0.060 |
Why?
|
| Uterus | 1 | 2010 | 799 | 0.060 |
Why?
|
| Betacoronavirus | 2 | 2020 | 514 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2009 | 1032 | 0.060 |
Why?
|
| Cell Movement | 2 | 2010 | 2468 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 2419 | 0.060 |
Why?
|
| Smooth Muscle Tumor | 1 | 2024 | 15 | 0.060 |
Why?
|
| Child, Preschool | 5 | 2021 | 17083 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 4148 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 5779 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1276 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2013 | 5692 | 0.060 |
Why?
|
| Carcinoma | 1 | 2015 | 2609 | 0.060 |
Why?
|
| Blood Platelets | 1 | 2008 | 675 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 2050 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2009 | 3567 | 0.050 |
Why?
|
| Base Sequence | 1 | 2010 | 5406 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 3463 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2009 | 3040 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 2177 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2016 | 2883 | 0.050 |
Why?
|
| Child | 6 | 2021 | 30572 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 7054 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2023 | 288 | 0.050 |
Why?
|
| Neural Crest | 1 | 2021 | 83 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 12045 | 0.050 |
Why?
|
| Pancreas | 2 | 2015 | 739 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 5924 | 0.040 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2020 | 43 | 0.040 |
Why?
|
| Patients | 1 | 2022 | 247 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 2019 | 69 | 0.040 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2020 | 40 | 0.040 |
Why?
|
| Species Specificity | 1 | 2021 | 783 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2010 | 7233 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 578 | 0.040 |
Why?
|
| Recurrence | 2 | 2018 | 4878 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 4007 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2020 | 79 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2021 | 4102 | 0.040 |
Why?
|
| Infant | 3 | 2021 | 14003 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2024 | 574 | 0.040 |
Why?
|
| Indazoles | 1 | 2021 | 310 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2021 | 488 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2011 | 12036 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.040 |
Why?
|
| Second-Look Surgery | 1 | 2018 | 16 | 0.040 |
Why?
|
| Zebrafish | 1 | 2021 | 456 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2023 | 1490 | 0.040 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 147 | 0.040 |
Why?
|
| Mesoderm | 1 | 2019 | 391 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 1061 | 0.040 |
Why?
|
| Axilla | 1 | 2021 | 945 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 682 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 307 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 747 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 348 | 0.030 |
Why?
|
| Drug Synergism | 2 | 2010 | 1355 | 0.030 |
Why?
|
| Inpatients | 1 | 2022 | 686 | 0.030 |
Why?
|
| DNA Damage | 1 | 2024 | 1991 | 0.030 |
Why?
|
| Clonal Evolution | 1 | 2018 | 250 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 1124 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2021 | 699 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1381 | 0.030 |
Why?
|
| Mutation | 3 | 2021 | 15922 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 562 | 0.030 |
Why?
|
| Pyridines | 1 | 2022 | 1312 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 772 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 824 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2018 | 2313 | 0.030 |
Why?
|
| Mitomycin | 1 | 2015 | 216 | 0.030 |
Why?
|
| Mastectomy | 1 | 2021 | 1554 | 0.030 |
Why?
|
| Breast | 1 | 2021 | 1370 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 1439 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2015 | 666 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2015 | 350 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2015 | 209 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 3395 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 604 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2011 | 4905 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 707 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 2112 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1656 | 0.020 |
Why?
|
| Adiposity | 1 | 2013 | 238 | 0.020 |
Why?
|
| Biomarkers | 1 | 2023 | 5050 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2021 | 1943 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 4320 | 0.020 |
Why?
|
| Weight Loss | 1 | 2015 | 628 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 3946 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1576 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2017 | 1015 | 0.020 |
Why?
|
| Logistic Models | 1 | 2018 | 3430 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2010 | 327 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 716 | 0.020 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2010 | 144 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 4495 | 0.020 |
Why?
|
| Response Elements | 1 | 2010 | 192 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2010 | 123 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 121 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6193 | 0.020 |
Why?
|
| Microvessels | 1 | 2010 | 145 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 210 | 0.020 |
Why?
|
| Luciferases | 1 | 2010 | 454 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2010 | 579 | 0.020 |
Why?
|
| Lymphatic Vessels | 1 | 2010 | 138 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2010 | 277 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 1761 | 0.020 |
Why?
|
| Phenotype | 1 | 2020 | 6503 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2008 | 105 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 4532 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2021 | 5415 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 622 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 1801 | 0.020 |
Why?
|
| Estradiol | 1 | 2010 | 828 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 6639 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2011 | 697 | 0.020 |
Why?
|
| Estrogens | 1 | 2010 | 804 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 691 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 657 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2010 | 1715 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 2344 | 0.010 |
Why?
|
| Energy Intake | 1 | 2007 | 517 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 1571 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2010 | 1389 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2010 | 1032 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 2192 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 5759 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 5658 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 2454 | 0.010 |
Why?
|
| Critical Illness | 1 | 2007 | 734 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 7789 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 2010 | 1386 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 9047 | 0.010 |
Why?
|